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OBJECTIVES The purpose of this study was to examine treatment and outcomes in patients admitted to the
hospital with acute myocardial infarction (AMI) complicated by congestive heart failure
(CHF).
BACKGROUND Although cardiogenic shock complicating AMI has been studied extensively, the hospital
course of patients presenting with CHF is less well established.
METHODS The Second National Registry of Myocardial Infarction (NRMI-2) was analyzed to
determine hospital outcomes for patients with ST-elevation AMI admitted with CHF (Killip
classes II or III).
RESULTS Of 190,518 patients with AMI, 36,303 (19.1%) had CHF on admission. Patients presenting
with CHF were older (72.6  12.5 vs. 63.2  13.5 years), more often female (46.8% vs.
32.1%), had longer time to hospital presentation (2.80  2.6 vs. 2.50  2.4 h), and had
higher prevalence of anterior/septal AMI (38.8% vs. 33.3%), diabetes (33.1% vs. 19.5%), and
hypertension (54.6% vs. 46.1%) (all p  0.0005). Also, they had longer lengths of stay (8.1
 7.1 vs. 6.8 5.3 days, p 0.00005) and greater risk for in-hospital death (21.4% vs. 7.2%;
p 0.0005). Patients with CHF were less likely to receive aspirin (75.7% vs. 89.0%), heparin
(74.6% vs. 91.1%), oral beta-blockers (27.0% vs. 41.7%), fibrinolytics (33.4% vs. 58.0%), or
primary angioplasty (8.6% vs. 14.6%), and more likely to receive angiotensin-converting
enzyme inhibitors (25.4% vs. 13.0%). Congestive heart failure on admission was one of the
strongest predictors of in-hospital death (adjusted odds ratio 1.68; 95% confidence interval
1.62, 1.75).
CONCLUSIONS Patients with AMI presenting with CHF are at higher risk for adverse in-hospital outcomes.
Despite this, they are less likely to be treated with reperfusion therapy and medications with
proven mortality benefit. (J Am Coll Cardiol 2002;40:1389–94) © 2002 by the American
College of Cardiology Foundation
Left ventricular decompensation complicating acute myo-
cardial infarction (AMI) results in the clinical syndromes of
congestive heart failure (CHF) and cardiogenic shock.
Although cardiogenic shock has been the focus of several
studies (1,2), little attention has been paid to CHF. This
complication occurs in approximately 15% to 25% of pa-
tients with AMI (3–7) and is associated with an in-hospital
mortality rate of 15% to 40% (3–6) and a one-year mortality
rate of 25% to 55% (3,6,8). Several studies have described
the occurrence of CHF developing after AMI (8–12),
particularly in relation to treatment with fibrinolytics
(11,12), whereas others have investigated the utility of using
the Killip classification (13) as a prognostic indicator of
survival after AMI (14–16). However, only a few studies
have specifically examined the clinical outcome of patients
with AMI presenting with CHF on admission (6,7,13).
The Second National Registry of Myocardial Infarction
(NRMI-2) is a multicenter, community-based database of
patients presenting with AMI. In this report, we analyzed
the NRMI-2 population to determine the incidence and
characteristics of CHF complicating AMI and to identify
the predictors of hospital outcome.
METHODS
Data collection. The NRMI-2 is a prospective, observa-
tional database of consecutive patients admitted to 1,674
participating hospitals throughout the U.S. A total of
772,586 patients were enrolled from June 1994 to March
1998. All treatment decisions were made at the discretion of
the treating physicians.
The data collection process used in the study and quality
control features have been previously described (17). Pa-
tients were included in the registry if they had documented
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AMI by clinical, electrocardiographic, or serial enzyme level
criteria before hospital discharge. Patients transferred out to
a non-NRMI hospital were excluded to avoid incomplete or
inconsistent data. Patients were included in the present
analysis if they: 1) presented within 12 h of symptom onset;
2) had electrocardiographic evidence of AMI including
ST-segment elevation or left bundle-branch block; and 3)
were admitted in Killip class I, II, or III (i.e., Killip class IV
excluded). Congestive heart failure was defined as Killip
class II or III. In order to analyze as uniform a population of
AMI patients presenting with CHF as possible, we did not
include patients with non–ST-segment elevation AMI in
this study.
Statistical analysis. Differences in selected characteristics
between patients presenting with CHF and those without
were analyzed using chi-square tests for discrete variables
and two-tailed t tests for continuous variables. A p value
0.05 indicated statistical significance. The simultaneous
effects of CHF and several potential confounding factors on
hospital mortality were examined using logistic regression
analysis. Using stepwise selection, we entered variables into
the multivariate logistic regression model in the following
order: 1) presence of CHF on admission and demographic
data (age, gender, race); 2) medical history (smoking,
diabetes, hypertension, history of angina, history of AMI,
history of CHF, prior stroke, prior percutaneous translumi-
nal coronary angioplasty [PTCA], and prior coronary artery
bypass graft surgery); 3) presentation characteristics (ante-
rior or septal AMI, posterior or lateral AMI, chest pain at
presentation, transferred in); 4) medications within 24 h
(aspirin, subcutaneous heparin, intravenous [IV] heparin,
angiotensin-converting enzyme [ACE] inhibitor, oral [PO]
beta-blocker, IV beta-blocker, calcium-channel blocker,
fibrinolytics); and 5) primary reperfusion strategies (fibrino-
lysis, PTCA). Because so many variables were entered into
the multivariate logistic regression model, tests for multi-
collinearity between variables were performed. A covariance
matrix did not demonstrate significant multicollinearity,
and tolerance values of all variables in a linear regression
model were high, also indicating low multicollinearity.
Statistical analyses were performed with SAS software,
version 8.02 (SAS Institute, Cary, North Carolina).
RESULTS
Baseline characteristics. A total of 190,518 patients met
inclusion criteria; 36,303 (19.1%) had CHF. Baseline pa-
tient characteristics are shown in Table 1. Of the patients
with CHF, 70.6% were Killip class II and 29.4% were Killip
class III. Patients with CHF were more likely to be older
and female, and to have a higher prevalence of diabetes,
hypertension, prior AMI, and history of CHF. They more
often had an anterior or septal AMI and presented later to
the hospital than those without CHF. Although there were
no clinically significant differences in systolic or diastolic
blood pressure, patients with CHF had higher heart rates
than those without CHF.
Treatment. Patients presenting with CHF were less likely
to receive aspirin, heparin, beta-blockers, and fibrinolytics
but were more likely to receive ACE inhibitors and calcium-
channel blockers (Table 2). Procedures performed during
hospitalization are shown in Table 3. A greater proportion
of patients with CHF required supportive interventions,
including mechanical ventilation, pacemaker placement,
and intra-aortic balloon counterpulsation. Fewer patients
with CHF were treated with primary or elective PTCA or
surgical revascularization.
Hospital events. As shown in Table 4, patients presenting
with CHF experienced more adverse clinical outcomes,
including recurrent AMI, stroke, second- or third-degree
atrioventricular block, ventricular arrhythmias, cardiac rup-
ture, and unexpected cardiac arrest. In-hospital mortality
was three times higher for patients with CHF than those
without CHF (21.4% vs. 7.2%; p  0.0005). In addition,
length of hospital stay was longer.
Multivariate analysis. The logistic regression analysis per-
formed to assess the effect of CHF while adjusting for
potential confounding factors is shown in Table 5. Conges-
tive heart failure on admission with AMI was one of the
strongest predictors of in-hospital death (adjusted odds ratio
[OR] 1.68; 95% confidence interval [CI] 1.62, 1.75), in
addition to anterior AMI (adjusted OR 1.85; 95% CI 1.78,
1.92) and older age (adjusted OR 1.58; 95% CI 1.55, 1.61).
Treatment with aspirin, PO (but not IV) beta-blockers, and
ACE inhibitors were negatively associated with in-hospital
death, as was chest pain at presentation. Although risk of
in-hospital death was reduced with both fibrinolytics (ad-
justed OR 0.91; 95% CI 0.87, 0.95) and primary PTCA
(adjusted OR 0.67; 95% CI 0.63, 0.72), the latter appeared
to impart a stronger survival benefit.
DISCUSSION
CHF complicating AMI. Drawn from over 1,600 hospi-
tals nationwide, our large study population was a represen-
tative sample of patients presenting with CHF complicating
AMI in the U.S. in the mid-1990s. Both the incidence of
CHF (19%) and distribution of Killip class II (13.5%) and
III (5.6%) were similar to those found in older randomized
studies of fibrinolytic therapy (3–5). Interestingly, these
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rates have decreased in more recent trials (18,19), probably
reflecting recruitment bias. Patients with CHF were more
likely to be older and female, and have a prior history of
cardiovascular and comorbid disease (6–9). Furthermore,
this patient subgroup was more likely to present with
high-risk AMI characteristics including anterior location
(20), tachycardia (21), absence of chest pain (22), and longer
period from symptom onset to hospital presentation (3).
In their landmark 1967 publication, Killip and Kimball
(13) demonstrated increasing hospital mortality with greater
degree of CHF severity (i.e., higher Killip class), and their
classification has endured as a simple and accurate tool for
early risk assessment of patients with AMI (23). Although
survival for patients with CHF has improved since 1975 (9),
the association between higher Killip class and poorer
outcomes has not changed. In our study, Killip class II or III
patients were at higher risk for adverse outcomes, including
death. Furthermore, CHF on admission was one of the
most powerful predictors of in-hospital mortality. In a
secondary analysis of the Global Utilization of Streptokinase
and Tissue Plasminogen Activator for Occluded Coronary
Arteries (GUSTO-1) trial, Lee et al. (15) found that higher
Killip class, in addition to older age, lower systolic blood
pressure, tachycardia, and anterior AMI accounted for 90%
of the prognostic value found in baseline data.
Table 1. Baseline Characteristics
Characteristic
No CHF
(N  154,215)
N (%)
CHF
(N  36,303)
N (%) p Value
Age (yrs, mean SD) 63.2  13.5 72.6  12.5 *
Male 104,637 (67.9%) 19,308 (53.2%) *
White 132,311 (89.4%) 31,287 (89.3%) 0.6
Medical history
Smoking 56,202 (36.4%) 8,228 (22.7%) *
Diabetes 30,134 (19.5%) 12,012 (33.1%) *
Hypertension 71,107 (46.1%) 19,837 (54.6%) *
Family history of CAD 52,775 (34.2%) 8,535 (23.5%) *
History of angina 20,967 (13.6%) 7,432 (20.5%) *
History of MI 30,488 (19.8%) 11,989 (33.0%) *
History of CHF 7,308 (4.7%) 10,649 (29.3%) *
Prior stroke 8,312 (5.4%) 4,253 (11.7%) *
Prior PTCA 13,012 (8.5%) 2,716 (7.5%) *
Prior CABG 12,659 (8.2%) 4,360 (12.0%) *
Clinical characteristics
Anterior or septal AMI 51,373 (33.3%) 14,099 (38.8%) *
Posterior or lateral AMI 34,678 (22.5%) 7,601 (20.9%) *
Killip class
I (No CHF) 154,215 (80.9%) — —
II (Rales, JVD) — 25,644 (13.5%)
III (Pulmonary edema) — 10,659 (5.6%)
Chest pain at presentation 138,823 (92.4%) 26,201 (74.8%) *
Symptom onset to 1st hospital arrival (h, mean  SD) 2.50  2.4 2.80  2.6 *
Systolic blood pressure (mm Hg, mean  SD) 141.1  30.9 140.9  35.0 0.3
Diastolic blood pressure (mm Hg, mean  SD) 82.6  18.0 81.4  19.5 *
Heart rate (beats/min, mean  SD) 78.7  20.3 94.0  27.0 *
*p values  0.001, unless otherwise noted.
AMI  acute myocardial infarction; CABG coronary artery bypass graft surgery; CAD  coronary artery disease; CHF 
congestive heart failure; JVD  jugular venous distention; MI  myocardial infarction; PTCA  percutaneous transluminal
coronary angioplasty.
Table 2. Medications Within 24 h
Medication No CHF CHF p Value
Aspirin 137,203 (89.0%) 27,492 (75.7%) *
Heparin
SQ 2,168 (1.4%) 1,336 (3.7%) *
IV 140,458 (91.1%) 27,093 (74.6%) *
ACE inhibitors 19,982 (13.0%) 9,231 (25.4%) *
Beta-blockers
PO 64,271 (41.7%) 9,809 (27.0%) *
IV 36,859 (23.9%) 5,558 (15.3%) *
Calcium-channel blockers 16,292 (10.6%) 4,914 (13.5%) *
Fibrinolytics 89,453 (58.0%) 12,128 (33.4%) *
*All p values  0.001.
ACE  angiotensin-converting enzyme; CHF  congestive heart failure; IV 
intravenous; PO  oral; SQ  subcutaneous.
Table 3. Procedures
Procedure No CHF CHF p Value
Echocardiography 67,260 (43.6%) 19,933 (54.9%) *
Stress test 21,581 (14.0%) 3,398 (9.4) *
Mechanical ventilation 22,999 (14.9%) 8,876 (24.4) *
Pacemaker 8,211 (5.3%) 2,297 (6.3) *
IABP 10,449 (6.8%) 3,313 (9.1) *
Primary PTCA 22,491 (14.6%) 3,105 (8.6) *
Elective PTCA 37,098 (24.1%) 4,070 (11.2) *
CABG 21,010 (13.6%) 3,633 (10.0) *
*All p values 0.001.
CABG  coronary artery bypass graft surgery; CHF  congestive heart failure;
IABP  intra-aortic balloon counterpulsation; PTCA  percutaneous transluminal
coronary angioplasty.
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Adjunctive drug therapy. Aspirin and beta-blockers have
been demonstrated in randomized trials to improve survival
in patients with AMI (24,25), as has ACE inhibitor therapy
for patients with CHF complicating AMI (26,27). We
found that AMI patients presenting with CHF are at high
risk for adverse hospital outcomes, but despite their poor
prognosis, they are less aggressively treated with potentially
life-saving medications. In multivariate analysis, treatment
with ACE inhibitor, aspirin, and PO beta-blocker therapy
provided the strongest protection against in-hospital death
in this high-risk population. Despite this marked benefit,
25% of these high-risk patients did not receive aspirin, and
three-quarters did not receive beta-blockers or ACE inhib-
itors. Additionally, patients presenting with CHF were
more likely to receive calcium-channel blockers, which do
not have proven clinical benefit for patients with AMI and
are an American College of Cardiology/American Heart
Association (ACC/AHA) class III indication for patients
with CHF (28). In our analysis, treatment with calcium-
channel blockers had a neutral effect on hospital mortality.
Easily administered medications such as aspirin, beta-
blockers, and ACE inhibitors have always been underused
in the treatment of patients with AMI. In 1992, only 38%
of hospitalized patients with AMI were treated with beta-
blockers (29). In hospitalized Medicare patients with AMI,
approximately 80% received aspirin, 45% received beta-
blockers, and less than 60% received ACE inhibitors, even
when contraindications were absent (30). Other large stud-
ies have found similar suboptimal usage rates of these
medications for patients with AMI (31,32).
The reasons behind underuse of potentially life-saving
medications in our patient population are not entirely clear
and are probably multifactorial. Possible contributors in-
clude care providers’ overestimation of potential side effects
(such as hypotension) or unawareness of current standards
of care, lack of hospital protocols to ensure that treatment is
consistent with evidence-based guidelines, or non-clinical
factors such as patient gender and race or geographic
variation that may influence treatment decisions (29,31).
Although the presence of transient CHF, pulmonary
edema, reduced left ventricular ejection fraction, or higher
Killip class is associated with lack of beta-blocker therapy
(33,34), the risk of worsening heart failure with initiation of
beta-blocker therapy may be overstated. Among AMI
patients with a known history of CHF, clinical heart failure
was precipitated in only 15% (35), and these patients
benefited from treatment with a greater reduction in abso-
lute mortality (36,37). Even patients with severe left ven-
tricular dysfunction demonstrate long-term mortality ben-
efit from beta-blocker treatment (34). More recently, a large
multicenter trial demonstrated a 29% risk reduction for the
combined end point of all-cause mortality and non-fatal
AMI in patients with left ventricular dysfunction random-
ized to treatment with the beta-blocker carvedilol after AMI
(38). The ACE inhibitors have been an ACC/AHA class I
indication for patients with CHF since 1996 (28). Further
investigation of potential barriers to optimal care of patients
with CHF complicating AMI is warranted.
Reperfusion therapy. This study confirmed the previous
observation that patients with AMI presenting with CHF
are less likely to undergo primary reperfusion, either with
fibrinolysis or PTCA, than Killip class I patients (6,7).
Although one small randomized study showed survival
benefit after fibrinolysis in patients presenting with CHF
(39), others have not (5), and it has not conclusively been
shown that this subgroup of patients benefits from fibrino-
lysis (40). In this study, the largest report on patients with
CHF complicating AMI, there was a small (9%) reduction
in relative risk of mortality that was statistically significant.
The failure of fibrinolytic therapy to dramatically decrease
mortality in patients who present with CHF could be
explained by physiologically more significant left ventricular
dysfunction, lower reperfusion rates, associated mechanical
Table 4. Hospital events
Event No CHF CHF p Value
Recurrent MI 4,107 (2.7%) 1,075 (3.0%) 0.002
Stroke 2,213 (1.4%) 795 (2.2%) *
2nd or 3rd degree AV block 7,103 (4.6%) 2,055 (5.7) *
Sustained VT or VF 13,900 (9.0%) 4,335 (11.9%) *
Cardiac rupture/EMD 1,584 (1.0%) 646 (1.8%) *
Unexpected cardiac arrest 6,785 (4.4%) 2,998 (8.3%) *
Death 11,078 (7.2%) 7,761 (21.4%) *
Length of stay
(days, mean  SD)
6.8  5.3 8.1  7.1 *
*p values  0.001, unless otherwise noted.
AV  atrioventricular; CHF  congestive heart failure; EMD  electrical-
mechanical dissociation; MI  myocardial infarction; VF  ventricular fibrillation;
VT  ventricular tachycardia.
Table 5. Multivariate Logistic Regression Analysis of Predictors
of Hospital Death
Variable Adjusted OR 95% CI
Anterior MI 1.85 1.78, 1.92
CHF on admission 1.68 1.62, 1.75
Age (decade) 1.58 1.55, 1.61
Posterior MI 1.57 1.46, 1.68
Transferred in 1.40 1.34, 1.47
History of stroke 1.36 1.29, 1.44
History of CABG 1.25 1.18, 1.32
Diabetes 1.21 1.17, 1.26
History of angina 1.06 1.01, 1.11
Previous MI 1.04 1.00, 1.09
History of CHF 0.92 0.88, 0.97
IV fibrinolytics 0.91 0.87, 0.95
Male 0.84 0.81, 0.87
History of PTCA 0.82 0.76, 0.88
Current smoking 0.80 0.77, 0.84
SQ heparin 0.75 0.67, 0.83
IV heparin 0.73 0.69, 0.76
Primary PTCA 0.67 0.63, 0.72
Chest pain at presentation 0.53 0.50, 0.55
ACE inhibitor 0.51 0.48, 0.53
Aspirin 0.42 0.41, 0.44
PO beta blocker 0.42 0.41, 0.44
CABG coronary artery bypass graft surgery; CHF congestive heart failure; CI
confidence interval; MI  myocardial infarction; OR  odds ratio; PTCA 
percutaneous transluminal coronary angioplasty; other abbreviation as in Table 2.
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complications (such as mitral regurgitation), or completed
infarction (40). We found that the risk of in-hospital
mortality was reduced more by primary PTCA than by
fibrinolysis. Similar favorable results have been observed
with primary PTCA in cardiogenic shock (1,2,40) and in
Killip class II or III patients (41), presumably due to
improved infarct artery patency. DeGeare and co-workers
(42) reported lower than expected in-hospital mortality rates
of 2.4%, 7.0%, and 19.2% for 2,654 patients undergoing
primary percutaneous coronary intervention in Killip class I,
II, and III, respectively. However, further investigation is
needed to clarify whether primary PTCA is superior to
fibrinolytic therapy for patients with AMI complicated by
CHF.
Study limitations. Although the NRMI-2 registry in-
cludes more than 1,600 hospitals throughout the U.S.,
participating hospitals may not be entirely representative of
all hospitals in the country. Registry hospitals have been
shown to be larger, more likely to be affiliated with a
medical school, more likely to be certified by the Joint
Commission on Accreditation of Health Care Organiza-
tions, and more likely to have facilities for cardiac catheter-
ization and cardiac surgery than non-registry hospitals (17).
However, a recent analysis found that the NRMI-2 registry
compared favorably with the Cooperative Cardiovascular
Project (CCP), a large national registry which employs very
rigorous data collection methods, with regard to demo-
graphic, past medical, procedural, and medication use data
(43).
A second limitation of our analysis is that NRMI-2 is an
observational registry rather than a randomized treatment
trial, and thus CHF was defined by chart-abstracted Killip
class. Killip class in NRMI-2 has not been externally
validated. In the recent comparison with the CCP, CHF
complicating AMI during hospitalization was under-
reported in NRMI-2 (43). However, if NRMI-2 also
under-reported CHF on admission, any differences between
patients presenting with CHF versus those without would
be attenuated rather than falsely exaggerated. Also,
NRMI-2 did not include data on the different mechanisms
of CHF in patients with AMI, so their impact on manage-
ment and outcomes cannot be determined.
Conclusion. Our study demonstrates that patients present-
ing with AMI complicated by CHF are at high risk for
hospital mortality and adverse outcomes. Despite their
increased risk, these patients are less frequently treated with
medications with proven mortality benefit or with primary
reperfusion strategies. Further study to determine and
overcome barriers to treatment with aspirin, beta-blockers,
and ACE inhibitors in this high-risk group of patients is
warranted. In addition, primary PTCA appears to be
associated with greater mortality benefit than fibrinolytics, a
finding that merits further investigation with prospective
clinical trials. Early identification of patients with CHF and
aggressive targeting of this patient population for medical
treatment and reperfusion therapy may reduce hospital
mortality and adverse events.
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